We are live on ! Find out more
ARRY

Array Biopharma Inc
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

Back to rankings

132 hedge funds and large institutions have $382M invested in Array Biopharma Inc in 2016 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 43 increasing their positions, 42 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

8% less call options, than puts

Call options by funds: $5.4M | Put options by funds: $5.87M

13% less funds holding

Funds holding: 151 → 132 (-19)

34% less capital invested

Capital invested by funds: $578M → $382M (-$195M)

50% less first-time investments, than exits

New positions opened: 17 | Existing positions closed: 34

Holders
132
Holders Change
-19
Holders Change %
-12.58%
% of All Funds
3.52%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
17
Increased
43
Reduced
42
Closed
34
Calls
$5.4M
Puts
$5.87M
Net Calls
-$465K
Net Calls Change
+$4.86M

Top Buyers

Rank Fund Capital Flow
1
SCM
Sarissa Capital Management
Connecticut
+$6.52M
2
AC
Armistice Capital
New York
+$5.99M
3
RG
Redmile Group
California
+$3.9M
4
BI
BVF Inc
California
+$3.5M
5
PAM
Panagora Asset Management
Massachusetts
+$2.68M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$15.8M
2
Millennium Management
Millennium Management
New York
-$11.1M
3
First Manhattan
First Manhattan
New York
-$4.64M
4
OAM
Oxford Asset Management
United Kingdom
-$4.46M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.02M
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
51
ClariVest Asset Management
California
$550K +$22.1K +7,375 +4%
BFIC
52
Bedell Frazier Investment Counselling
California
$532K +$3.75K +1,250 +0.7%
HCM
53
Hollencrest Capital Management
California
$502K – – –
RhumbLine Advisers
54
RhumbLine Advisers
Massachusetts
$479K +$14.3K +4,780 +3%
NI
55
Numeric Investors
Massachusetts
$448K -$129K -42,900 -22%
Fisher Asset Management
56
Fisher Asset Management
Washington
$430K – – –
SAMC
57
Shinko Asset Management Company
Japan
$400K – – –
AL
58
Airain Ltd
Guernsey
$395K -$227K -75,835 -36%
New York State Common Retirement Fund
59
New York State Common Retirement Fund
New York
$394K – – –
ProShare Advisors
60
ProShare Advisors
Maryland
$364K -$35.5K -11,865 -9%
Citigroup
61
Citigroup
New York
$300K +$260K +86,638 +575%
TAM
62
Tocqueville Asset Management
New York
$295K -$749 -250 -0.2%
MLICM
63
Metropolitan Life Insurance Company (MetLife)
New York
$290K +$2.78K +927 +1%
Manulife (Manufacturers Life Insurance)
64
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$275K +$5.49K +1,832 +2%
NFA
65
Nationwide Fund Advisors
Ohio
$269K -$4.2K -1,400 -2%
CGT
66
Capital Guardian Trust
California
$266K -$255K -85,000 -49%
BG
67
BlackRock Group
United Kingdom
$262K +$56.5K +18,852 +27%
Creative Planning
68
Creative Planning
Kansas
$255K -$95.9K -32,000 -27%
State Board of Administration of Florida Retirement System
69
State Board of Administration of Florida Retirement System
Florida
$251K – – –
AIG
70
American International Group
New York
$251K +$3K +1,000 +1%
UBS AM
71
UBS AM
Illinois
$242K -$62.9K -20,998 -20%
PPA
72
Parametric Portfolio Associates
Washington
$201K -$1.33K -445 -0.6%
VFA
73
Virtus Fund Advisers
Connecticut
$198K -$43.5K -14,518 -18%
DekaBank Deutsche Girozentrale
74
DekaBank Deutsche Girozentrale
Germany
$198K -$13.2K -4,400 -6%
VEA
75
Virtus ETF Advisers
New York
$196K +$199K +66,376 New
1 2
3
4 5

ARRY Hedge Fund Activity: Q1 2016 in Review

132 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q1 2016, worth a combined $382M — down 34% from $578M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of ARRY and 17 opened new positions — a net loss of 17 holders — while 42 trimmed existing stakes and 43 added.

The largest buyer was Sarissa Capital Management, adding an estimated $6.52M. The largest seller was Fidelity Investments, cutting an estimated $15.8M.

  • 132 institutional investors held Array Biopharma Inc (ARRY) as of Q1 2016, down from 151 in Q4 2015.
  • Funds reported $382M of Array Biopharma Inc stock for Q1 2016, down 34% quarter-over-quarter.
  • 17 funds opened new Array Biopharma Inc positions in Q1 2016 and 34 closed out, a net change of -17 holders.
  • The largest Array Biopharma Inc buyer in Q1 2016 was Sarissa Capital Management, an estimated $6.52M added.
  • The largest Array Biopharma Inc seller in Q1 2016 was Fidelity Investments, an estimated $15.8M sold.

Based on aggregated 13F filings for Q1 2016.